Vimarsana
Biggest News Aggregation in the World

Failure Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Failure Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Failure Trial Today - Breaking & Trending Today

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results - Vimarsana News

BioCardia Reports First Quarter 2024 Business Highlights and Financial Results

Published: May 15, 2024

SUNNYVALE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for th...

Source: businessinsider.com
Related Topics:
United StatesPeter AltmanBiocardia IncMaryland Stem Cell Research FundEuropean Society Of Cardiology Heart Failure CongressMedicaid ServicesExchange CommissionDevice AgencyCompany Annual Report On FormExchange Commission OnCell TherapyIschemic Heart FailureFailure TrialHeart Failure TherapeuticsTherapy Heart FailureChronic Myocardial IschemiaTherapy Chronic Myocardial Ischemia TrialExcellent PhaseEuropean SocietyCardiology Heart Failure CongressTherapy Heart Failure TrialReduced Ejection FractionMesenchymal Stem Cell TherapyTherapy TrialHeart Failure
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results -March 27, 2024 at 01:30 pm EDT - Vimarsana News

BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results -March 27, 2024 at 01:30 pm EDT

Published: March 27, 2024

BioCardia Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results March 27, 2024 BioCardia®, Inc. [Nasdaq: BCDA], a developer of...

Source: marketscreener.com
Related Topics:
United StatesFinkelstein SchoenfeldPeter AltmanDevice AgencyMedicaid ServicesExchange Commission OnBiocardia IncMaryland Stem Cell Research FundExchange CommissionBiocardia Reports Fourth QuarterFull YearFinancial ResultsMorph Access InnovationsAutologous Cell TherapyTherapy Heart FailureHeart Failure TherapyMajor Adverse CoronaryCerebrovascular EventsFailure TrialCell TherapyChronic Myocardial IschemiaTherapy Chronic Myocardial Ischemia TrialMesenchymal Stem CellsHeart Failure TherapeuticsTherapy Heart Failure Trial
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Vimarsana News

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes

Published: December 18, 2023

SUNNYVALE, Calif., Dec. 18, 2023 -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced...

Source: marketscreener.com
Related Topics:
United StatesMiranda PetoDavid McclungPeter AltmanDevice AgencyMedicaid ServicesCardiamp Cell Therapy ProgramBiocardia IncExchange CommissionGlobenewswire IncCenters For MedicareMaryland Stem Cell Research FundMedical Device AgencyFailure TrialChief ExecutiveCell TherapyStem Cell Research FundAutologous CellsHeart Failure TrialLooking StatementsQuarterly ReportsInvestor Relations EmailChief Financial Officer Email
BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST - Vimarsana News

BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K -December 18, 2023 at 07:02 am EST

Published: December 18, 2023

BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes SUNNYVALE, Calif. - December...

Source: marketscreener.com
Related Topics:
United StatesPeter AltmanMiranda PetoDavid McclungDevice Agency Consultation MinutesMedicaid ServicesExchange Commission OnBiocardia IncDevice AgencyCardiamp Cell Therapy ProgramMaryland Stem Cell Research FundCenters For MedicareBiocardia Announces ExpectedFailure Japan Approval Timeline BasedMedical Device Agency ConsultationJapan PharmaceuticalMedical Device AgencyFailure TrialChief ExecutiveCell TherapyTrial EnrollmentAutologous CellsHeart Failure TrialLooking StatementsExchange Commission
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA) - Vimarsana News

BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval - BioCardia (NASDAQ:BCDA)

Published: November 29, 2023

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an

Source: benzinga.com
Related Topics:
United StatesMiranda PetoDavid McclungBiocardia CardiPeter AltmanCardiamp Cell Therapy ProgramDevice AgencyMaryland Stem Cell Research FundBiocardia IncExchange Commission OnMedicaid ServicesCenters For MedicareMedical Device AgencyFailure TrialChief ExecutiveCell TherapyLooking StatementsExchange CommissionQuarterly ReportsInvestor Relations EmailChief Financial Officer Email